Sectoral Asset Management Inc Altimmune, Inc. Transaction History

Sectoral Asset Management Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$8.22 - $13.81 $645,763 - $1.08 Million	-78,560 Reduced 46.0%	92,240 $939,000
Q4 2023 Feb 14, 2024	BUY	$2.14 - $11.62 $365,512 - $1.98 Million	170,800 New	170,800 $1.92 Million
Q1 2023 May 12, 2023	BUY	$4.19 - $16.83 $572,354 - $2.3 Million	136,600 Added 39.88%	479,100 $2.02 Million
Q4 2022 Feb 10, 2023	BUY	$8.74 - $16.45 $641,516 - $1.21 Million	73,400 Added 27.28%	342,500 $5.63 Million
Q3 2022 Nov 10, 2022	BUY	$10.67 - $22.41 $1.27 Million - $2.67 Million	119,100 Added 79.4%	269,100 $3.44 Million
Q2 2022 Aug 15, 2022	BUY	$3.94 - $11.77 $591,000 - $1.77 Million	150,000 New	150,000 $1.76 Million

186

39.3M

913K

743K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $370M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Sectoral Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Sectoral Asset Management Inc with notifications on news.